Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Apata, Olusegun
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Recruiting	3	526	Europe, US, RoW	Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo	Dompé Farmaceutici S.p.A	Infectious Pneumonia, Severe COVID-19	09/24	10/24
NCT05496868: Add-on Reparixin in Adult Patients With ARDS	Recruiting	2	66	Europe, US	Reparixin 600mg, REP, Matching Placebo, Control	Dompé Farmaceutici S.p.A	Acute Respiratory Distress Syndrome, Adult	04/25	05/25